hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06379451, orgStudyIdInfo id: [2023]YLJSA088, briefTitle: An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-18, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-23, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Changzhou No.2 People's Hospital, class: OTHER, descriptionModule briefSummary: Multiple myeloma (MM) is a malignant disease characterized by the abnormal proliferation of clonal plasma cells. However, multiple myeloma remains an incurable disease and requires the exploration of more effective treatment methods to improve the efficacy of relapsed refractory multiple myeloma and prolong survival time.Currently, clinical application of CAR-T is mostly based on autologous T cell preparation, while relapsed/refractory AML patients have undergone multiple chemotherapy treatments, resulting in impaired self-T cell function, which affects the efficacy and prognosis of CAR-T therapy. Therefore, it is necessary to find new alternative treatments. NK cells are important immune cells in the body and are an important component of innate immunity. Compared with CAR-T cell therapy, CAR-NK cells have unique advantages in adoptive cell therapy. NKG2D receptor is an activating receptor expressed on NK cells, which can recognize NKG2D ligands (NKG2DL) expressed on tumor cells, activating NK cell killing activity through NKG2D-NKG2DL interaction. Therefore, the investigators plan to treat relapsed multiple myeloma by infusing NKG2D-CAR-NK cells to evaluate its efficacy and safety., conditionsModule conditions: Multiple Myeloma, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 9, type: ESTIMATED, armsInterventionsModule interventions name: NKG2D Chimeric Antigen Receptor NK Cell Injection, outcomesModule primaryOutcomes measure: Incidence of Dose Limiting Toxicity (DLTs), primaryOutcomes measure: Treatment Emergent Adverse Events (TEAEs), secondaryOutcomes measure: Objective Response Rate of subjects, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Changzhou Second People's Hospital, city: Changzhou, state: Jiangsu, zip: 213000, country: China, contacts name: Wei Qin, doctor, role: CONTACT, phone: +8618796912763, email: qinwei19840601@163.com, geoPoint lat: 31.77359, lon: 119.95401, hasResults: False
protocolSection identificationModule nctId: NCT06379438, orgStudyIdInfo id: 06/16022018, briefTitle: Treatment of Aphtous Ulcers With Photodynamic Therapy, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-03-05, primaryCompletionDateStruct date: 2019-03-01, completionDateStruct date: 2019-03-08, studyFirstPostDateStruct date: 2024-04-23, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Yuzuncu Yıl University, class: OTHER, descriptionModule briefSummary: The search for methods that can shorten the treatment process of aphthous ulcers, the etiology of which is not fully understood, continues. The aim of this study was to determine whether photodynamic therapy (PDT) is a clinically effective alternative in the treatment of oral aphthous ulcers., conditionsModule conditions: Oral Ulcer, conditions: Aphthous Recurrent Ulcers, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Photodynamic therapy (indocyanine green+laser), outcomesModule primaryOutcomes measure: Ulcer wound healing with diameter measurement, primaryOutcomes measure: Level of recovery, secondaryOutcomes measure: Pain evaluation with Visual Analogue Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Yuzuncu Yil University, city: Van, state: Merkez, zip: 65080, country: Turkey, geoPoint lat: 38.49457, lon: 43.38323, hasResults: False
protocolSection identificationModule nctId: NCT06379425, orgStudyIdInfo id: 23-0050, briefTitle: Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-03-01, completionDateStruct date: 2026-03-01, studyFirstPostDateStruct date: 2024-04-23, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Northwell Health, class: OTHER, descriptionModule briefSummary: This is a double-arm randomized control trial evaluating the impact of preoperative opioid-free analgesia on time to trial of void in ambulatory urogynecologic surgeries. The investigators hypothesize that receipt of acetaminophen, celecoxib and gabapentin preoperatively versus acetaminophen alone will reduce the time to trial of void in patients undergoing same-day minor urogynecologic procedures., conditionsModule conditions: Pain, Postoperative, conditions: Postoperative Pain, Acute, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Acetaminophen, interventions name: Celecoxib, interventions name: Gabapentin, outcomesModule primaryOutcomes measure: Time to initiation of active trial of void, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Northwell Health South Shore Surgery Center, status: RECRUITING, city: Bay Shore, state: New York, zip: 11706, country: United States, contacts name: Kathleen R Catalano, MSN, RN-BC, role: CONTACT, phone: 631-647-5550, email: kcatalano@southshoresurg.com, contacts name: Nirmala Pillalamarri, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Steliana Fakas, MD, role: SUB_INVESTIGATOR, geoPoint lat: 40.7251, lon: -73.24539, hasResults: False
protocolSection identificationModule nctId: NCT06379412, orgStudyIdInfo id: Zhujianghmy, briefTitle: A Cross-sectional Study on the Association of Peptidoglycan Fragments Derived From Gut Microbiota With Colorectal Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-01, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-23, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Zhujiang Hospital, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to explore the association of peptidoglycan fragments derived from gut microbiota with colorectal cancer (CRC). The main question it aims to answer is: Are peptidoglycan fragments from the gut microbiota associated with the progression of colorectal cancer? Participants will provide biological specimens (blood, feces, colon tissue obtained during surgery), conditionsModule conditions: Colorectal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: observational study, no intervention, outcomesModule primaryOutcomes measure: HPLC-MS/MS was used to detect peptidoglycan fragment content in biological specimens of 200 participants, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhujiang Hospital of Southern Medical University, status: RECRUITING, city: Guangzhou, state: Guangdong, zip: 510000, country: China, contacts name: He Xiaolong, Professor, role: CONTACT, phone: 186 2007 1640, email: 307660349@qq.com, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06379399, orgStudyIdInfo id: IRB-2023-1072, briefTitle: Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-23, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Wangxia LV, class: OTHER, descriptionModule briefSummary: This study is a single-center, prospective, single-arm exploratory study aimed at evaluating the efficacy and safety of trifluridine/tipiracil in combination with cetuximab in the treatment of third-line and above RAS/BRAF wild-type metastatic colorectal cancer., conditionsModule conditions: Colorectal Cancer Metastatic, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 26, type: ESTIMATED, armsInterventionsModule interventions name: Cetuximab, interventions name: Trifluridine/Tipiracil, outcomesModule primaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Overall Response Rate (ORR), secondaryOutcomes measure: Disease Control Rate( DCR), secondaryOutcomes measure: Quality of life: EORTC QLQ-C30, secondaryOutcomes measure: Adverse Events(safety), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhejiang Cancer Hospital, status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 310022, country: China, contacts name: Wangxia Lv, role: CONTACT, phone: +86-13757141026, email: lvwangxia@163.com, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06379386, orgStudyIdInfo id: TRACE TAVR Registry, briefTitle: Long-term Prognosis and Valve Durability of TAVR, statusModule overallStatus: RECRUITING, startDateStruct date: 2016-01, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2030-12, studyFirstPostDateStruct date: 2024-04-23, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Xijing Hospital, class: OTHER, descriptionModule briefSummary: This registry aims to evaluate the long-term prognosis and valve durability of transcatheter aortic valve replacement (TAVR) in a real-world setting. Baseline characteristics, procedural data, and clinical outcomes will be collected in a prospective and observational manner., conditionsModule conditions: Aortic Valve Stenosis and Insufficiency, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Transcatheter aortic valve replacement, outcomesModule primaryOutcomes measure: All-casuse mortality, primaryOutcomes measure: Valve-related long-term clinical efficacy, secondaryOutcomes measure: Combined early safety and clinical efficacy outcomes, secondaryOutcomes measure: Rate of technical success, secondaryOutcomes measure: Rate of device success, secondaryOutcomes measure: Combined clinical efficacy outcomes, secondaryOutcomes measure: Valve-related long-term clinical efficacy, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Xijing Hospital, status: RECRUITING, city: Xi'an, state: Shannxi, zip: 710032, country: China, contacts name: Rutao Wang, M.D., Ph.D., role: CONTACT, phone: +86-15091095796, email: rutaowang@qq.com, contacts name: Ruining Zhang, BSc, role: CONTACT, phone: +86-15802990370, email: ruining-zhang@qq.com, contacts name: Ling Tao, M.D., Ph.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.25833, lon: 108.92861, hasResults: False
protocolSection identificationModule nctId: NCT06379360, orgStudyIdInfo id: SZAMLLRM01, briefTitle: Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-11-01, primaryCompletionDateStruct date: 2024-05-01, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-04-23, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital of Soochow University, class: OTHER, descriptionModule briefSummary: HMA maintenance therapy is expected to benefit overall survival (OS) and relapse free survival (RFS) in AML patients with favorable risk., conditionsModule conditions: Acute Myeloid Leukemia, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Apply hypomethylating agent, azacitidine or decitabine as maintenance therapy., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 77, type: ESTIMATED, armsInterventionsModule interventions name: Hypomethylating agent, Azacitidine or Decitabine, outcomesModule primaryOutcomes measure: Relapse free survival (RFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Cumulative incidence of relapse (CIR), eligibilityModule sex: ALL, minimumAge: 16 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Soochow University, status: RECRUITING, city: Suzhou, state: Jiangsu, zip: 215006, country: China, contacts name: Sheng-Li Xue, M.D., role: CONTACT, phone: +86 512 6778 1139, email: slxue@suda.edu.cn, geoPoint lat: 31.30408, lon: 120.59538, hasResults: False
protocolSection identificationModule nctId: NCT06379347, orgStudyIdInfo id: FZ 23/41, briefTitle: HOspitalized Patients and Clinical flUid Status, Assessment Using Point Of Care UltraSound, acronym: HOCUS-POCUS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-04-23, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Flevoziekenhuis, class: OTHER, descriptionModule briefSummary: Point of care ultrasound (POCUS) of the inferior vena cava (IVC) is a tool for assessing volume status through ultrasonography. Using a point of care ultrasound device, the physician can perform an ultrasound of the vena cava at the bedside. Previous research has demonstrated a correlation between right atrial pressure and the vena cava's diameter. Nonetheless, the majority of research has been conducted in critically ill populations to predict fluid responsiveness in patients with more complex hemodynamics. There is limited data available on the value of IVC ultrasound in the sub-acute setting on the regular ward for clinical decision-making regarding whether a patient is hypovolemic or hypervolemic. This study's objective is to assess the diagnostic utility of point-of-care ultrasonography of the IVC, by using a standardized methodology, performed by qualified ward physicians in a conventional nursing ward., conditionsModule conditions: Volume Status, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: POCUS perfomed on clinica indication, outcomesModule primaryOutcomes measure: Volume status, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Flevoziekenhuis, status: RECRUITING, city: Almere, country: Netherlands, contacts name: Koen de Heer, MD PhD, role: CONTACT, geoPoint lat: 52.37535, lon: 5.25295, hasResults: False
protocolSection identificationModule nctId: NCT06379334, orgStudyIdInfo id: I-22PJ911, briefTitle: Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Population, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2020-12-06, primaryCompletionDateStruct date: 2024-12-06, completionDateStruct date: 2026-12-06, studyFirstPostDateStruct date: 2024-04-23, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Peking Union Medical College Hospital, class: OTHER, descriptionModule briefSummary: Chronic hepatitis B (CHB) can lead to hepatocellular carcinoma (HCC), imposing a significant health and economic burden globally. Early detection of hepatitis B virus-related HCC (HBV-HCC) in CHB with potential biomarkers has become a pressing and difficult challenge. Recent advancements in urinary proteomics offer a promising approach for HBV-HCC biomarker identification, utilizing Liquid chromatography with tandem mass spectrometry for urine proteome analysis. Differential analysis using limma in R software will uncover upregulated proteins in HBV-HCC., conditionsModule conditions: Hepatocellular Carcinoma, conditions: Hepatitis B, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule interventions name: Urine test, outcomesModule primaryOutcomes measure: upregulated proteins, primaryOutcomes measure: downregulated proteins, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking Union Medical College Hospital, city: Beijing, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06379321, orgStudyIdInfo id: 24-362, briefTitle: A Retrospective/Prospective, Post-market Evaluation of Outcomes of the Triathlon Hinge Knee (THK) System, acronym: Hinge, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2034-05-01, completionDateStruct date: 2034-05-01, studyFirstPostDateStruct date: 2024-04-23, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: The Cleveland Clinic, class: OTHER, collaborators name: Stryker Orthopaedics, descriptionModule briefSummary: This study is a prospectively and retrospectively enrolled, post-market, open-label, non-randomized, single institution evaluation of clinical outcomes of primary or revision knee surgery patients who meet the eligibility criteria and received devices from the Triathlon Hinge Knee System according to its indications for use (IFU).Clinical evaluation for all cases will include data collection of patient demographics, surgical details, early postoperative status, functional and clinical outcomes, and survivorship at 1, 2, 6, and 10-years., conditionsModule conditions: Knee Arthropathy, conditions: Recurrence, conditions: Knee Infection, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Triathlon Hinge Knee (THK) System, outcomesModule primaryOutcomes measure: Survivorship, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cleveland Clinic Florida, city: Weston, state: Florida, zip: 33331, country: United States, contacts name: Kaitlin Bernabe, role: CONTACT, phone: 954-610-8016, email: BERNABK@ccf.org, contacts name: Jorge Manrique-Succar, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 26.10037, lon: -80.39977, locations facility: Cleveland Clinic, city: Cleveland, state: Ohio, zip: 44195, country: United States, contacts name: Laura Stiegel, role: CONTACT, phone: 216-442-5511, email: stiegel@ccf.org, contacts name: Alison Klika, role: CONTACT, phone: 216 444-4954, email: klikaa@ccf.org, contacts name: Matthew Deren, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.4995, lon: -81.69541, hasResults: False
protocolSection identificationModule nctId: NCT06379308, orgStudyIdInfo id: IRBN552024/CHUSTE., briefTitle: Anterior Cruciate Ligament (ACL) Revision Surgery: French National Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-04-23, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire de Saint Etienne, class: OTHER, descriptionModule briefSummary: This is a national multicentric study led by the French Arthroscopy Society (SFA) evaluating clinical practice in anterior cruciate ligament (ACL) revision surgery (epidemiological data, morphological data, operative data, clinical and functional outcomes, and surgical complication rates)., conditionsModule conditions: Anterior Cruciate Ligament Rupture, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: questionaries, interventions name: datas of medical record, outcomesModule primaryOutcomes measure: Results of Functional score questionary Anterior Cruciate Ligament Return to Sport and Injury (ACL-RSI), primaryOutcomes measure: Results of Functional score questionary Tegner Activity Scale (TAS), primaryOutcomes measure: Results of Functional score questionary Simple Knee Value (SKV), primaryOutcomes measure: Results of Functional score questionary International Knee Documentation Commitee (IKDC), secondaryOutcomes measure: Surgical complications, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU Saint-Etienne, city: Saint-Étienne, country: France, contacts name: Thomas NERI, MD PhD, role: CONTACT, phone: (0)477120784, phoneExt: +33, email: thomas.neri@chu-st-etienne.fr, contacts name: Thomas NERI, MD PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.43389, lon: 4.39, hasResults: False